MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,，我們不為任何個人用途提供產(chǎn)品和服務,。

SM-164

CAS No. : 957135-43-2

產(chǎn)品活性：SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC₅₀ value of 1.39 nM and functions as an extremely potent antagonist of XIAP.

研究領域：Apoptosis

作用靶點：IAP  |  Apoptosis

In Vitro: SM-164 is a non-peptide, cell-permeable, bivalent small-molecule, which mimics Smac protein for targeting XIAP. SM-164 binds to XIAP containing both BIR domains with an IC₅₀ value of 1.39 nM, being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells, while having a minimal toxicity to normal human primary cells at 10,000 nM. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 has a K_i value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a K_i value of 0.31 nM to cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with K_i values of 1.1 nM. Addition of exogenous TNFα can significantly enhance the activity of these Smac mimetics, especially for SM-164, in resistant cancer cell lines such as HCT116 and MDA-MB-453.

In Vivo: SM-164 is evaluated for its ability to inhibit tumor growth. SM-164 is highly effective in inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. Treatment with SM-164 at 1 mg/kg completely inhibits tumor growth during the treatment. Treatment with SM-164 at 5 mg/kg reduces the tumor volume from 147±54 mm³ at the beginning of the treatment (day 25) to 54±32 mm³ at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long lasting and not transient. SM-164 at 5 mg/kg is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm³ (P<0.02).

相關產(chǎn)品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Peptidomimetic Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  SY-5609  |  BRD4 Inhibitor-18  |  8α-Tigloyloxyhirsutinolide 13-O-acetate  |  AAPK-25  |  Dutasteride-¹³C₆  |  Oleic acid-¹³C  |  Abacavir sulfate  |  Meloxicam-d₃-1  |  Thailanstatin D  |  SB-218078  |  Toyocamycin  |  Sorafenib-d₄  |  Busulfan  |  PTC-028  |  Dinaciclib  |  CR-1-31-B  |  142I5  |  Farudodstat  |  Ecteinascidin 770  |  AT9283  |  Staurosporine  |  SNS-032  |  AZA1  |  Bleomycin A5  |  Xevinapant  |  Mangiferin  |  Cambinol  |  hGGPPS-IN-1  |  Bafetinib  |  Dinoprost-d₄

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物,；
•   50,000 多種高選擇性抑制劑,、激動劑涉及各熱門信號通路及疾病領,；
•   產(chǎn)品種類涵蓋各種重組蛋白,，多肽,，常用試劑盒 ,，更有 PROTAC、ADC 等特色產(chǎn)品,，廣泛應用于新藥研發(fā),、生命科學等科研項目；
•   提供虛擬篩選,，離子通道篩選,，代謝組學分析檢測分析，藥物篩選等專業(yè)技術服務,；
•   設有專業(yè)的實驗中心和嚴格的質控,、驗證體系；
•   提供 LC/MS、NMR,、HPLC,、手性分析、元素分析等各項質檢報告,，確保產(chǎn)品的高純度,、高品質；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證,；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果,；
•   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供*新的活性化合物,；
•   與世界各大制藥公司及著名科研機構建立了長期的合作,。